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Abstract
Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most widespread enzyme
defect that can result in red cell breakdown under oxidative stress when exposed to certain
medicines including antimalarials. We evaluated the diagnostic accuracy of CareStart
G6PD deficiency Rapid Diagnostic Test (RDT) as a point-of-care tool for screening
G6PD deficiency.
Methods
A cross-sectional study was conducted among 206 randomly selected and consented par-
ticipants from a group with known G6PD deficiency status between February 2013 and
June 2013. A maximum of 1.6ml of capillary blood samples were used for G6PD deficiency
screening using CareStartG6PD RDT and Trinity qualitative with Trinity quantitative meth-
ods as the “gold standard”. Samples were also screened for the presence of malaria para-
sites. Data entry and analysis were done using Microsoft Access 2010 and Stata Software
version 12. Kintampo Health Research Centre Institutional Ethics Committee granted
ethical approval.
Results
The sensitivity (SE) and specificity (SP) of CareStart G6PD deficiency RDT was 100% and
72.1% compared to Trinity quantitative method respectively and was 98.9% and 96.2%
compared to Trinity qualitative method. Malaria infection status had no significant (P=0.199)
change on the performance of the G6PD RDT test kit compared to the “gold standard”.
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Conclusions
The outcome of this study suggests that the diagnostic performance of theCareStartG6PD
deficiency RDT kit was high and it is acceptable at determining the G6PD deficiency status
in a high malaria endemic area in Ghana. The RDT kit presents as an attractive tool for point-
of-care G6PD deficiency for rapid testing in areas with high temperatures and less expertise.
TheCareStartG6PD deficiency RDT kit could be used to screen malaria patients before ad-
ministration of the fixed dose primaquine with artemisinin-based combination therapy.
Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the largest and most widespread en-
zyme defect affecting approximately 400 million persons worldwide. In malaria endemic areas,
the prevalence of G6PD ranges from 5.0% to 23.8% [1]. It is a sex-linked genetic defect occur-
ring on the X-chromosome. The global distribution of G6PD-deficient variants resembles the
geographical distribution of malaria and this supports the thinking that G6PD deficiency con-
fers some protection against malaria [2]. A number of G6PD deficient variants have been re-
ported in sub-Saharan Africa. Although there are over 400 G6PD variants worldwide, in sub-
Saharan Africa three variants, though not exclusive, occur; G6PDB, G6PDA and G6PDA-.
G6PDB is the wild type and the most common variant in Africa and worldwide. G6PDA has
a normal variant with about 90% of the G6PDB enzyme activity [1, 3], while G6PDA- is a de-
ficient variant with about 8–20% of the G6PDB enzyme activity [1]. Deficiency can result in
destruction of red cells and depending on the G6PD variant present, haemolysis maybe mild,
moderate, or severe [4, 5].
Malaria, the most common parasitic disease which is estimated to infect 3.2 billion people
in 97 countries and territories [6] is caused by infectious disease agents Plasmodium Vivax
(Pv), P. falciparum (Pf), P. ovale (Po), P.malariae (Pm), and the recently emerging P. knowlesi
(Pk). The burden of malaria is heaviest in the WHO African Region, where an estimated 90%
of all malaria deaths occur, and in children aged under 5 years, who account for 78% of all
deaths [6].
In Ghana, the entire nation is at the risk of malaria infection, particularly in the middle belt
of Ghana where transmission occur all year round with about 22.8% of malaria parasitaemia of
which 98.1% is as a result of Plasmodium falciparum infection [7, 8]. The country has been in-
volved in the malaria control program conducted by the WHO since early 2000. A very large
number of cases are attributable to Pf infection [7, 8] with no documented records of infections
due to Pv [9] as happens in the eastern part of Africa. The prevalence of G6PD deficiency in
Ghana has been reported as 6.5% [1]. In the middle belt with a population mainly of Akan and
Mo ethnic background [10], the G6PD prevalence has been reported as 6.8% and 19% [1, 11].
All reported deficient G6PDA- genotypes were A376G/G202A and there were no instances of
A542T, G680T or T968C in the study that looked at the G6PD genotype [1]. The absence of no
record of Pv relapsing malaria parasite infection [9] might have influenced the absence of the
use of primaquine from its Standard Treatment Guidelines for malaria [12]. It is of interest to
note that with the variant of G6PD deficient genotype (G6PDA-) prevalent in Ghana, there
have been no report of any drug implicated to cause G6PD-related hemolysis except for clinical
trials of chlorproguanil-dapsone artesunate (CDA) [5]. Being aware of primaquine inducing
acute haemolytic anaemia, participants with G6PD deficiency were exempted from taking part
in a study that used primaquine to radically clear malaria parasites [13].
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People with G6PD deficiency are mostly asymptomatic but exposure to oxidant drugs, such
as the anti-malarial drug primaquine, may induce hemolysis. The WHO recommended the use
of a single dose of primaquine to artemisinin-based combination therapy (ACT) as a compo-
nent of pre-elimination and elimination programmes provided the G6PD deficiency status of
patient is determined [14, 15].
Due to the seldom availability of G6PD testing in the field the implementation of the recom-
mendation was limited. This challenge led to a review of the recommendation to a single dose
of 0.25 mg base/kg primaquine, a dose considered unlikely to cause serious toxicity in subjects
with any of the G6PD variants [14]. Despite the revised recommendation by WHO, it is still
important to make G6PD testing available in the field to eliminate any haemolytic effect at any
dose of primaquine especially in Ghana where G6PD A- variant is common [1].
Phenotypic tests (being it quantitative or qualitative), unlike genetic techniques, to deter-
mine G6PD activity status are the most widely used and are the best indicators of G6PD func-
tion levels. Some of these testing products are suitable for point-of-care use in clinics because
they are rapid and straightforward [2]. However, most of these tests require relatively sophisti-
cated laboratory capacities equipped with electricity or specific laboratory equipment to regu-
late temperature [16] and also larger volumes of blood.
A rapid and inexpensive methods to determine the G6PD status of all persons is desirable
when one is considering use of drugs contraindicated in patients with G6PD deficiency. It is es-
pecially important and particularly needed in sub-Saharan Africa where G6PD deficiency is
high, malaria is endemic and use of oxidative malarial drugs such as primaquine is expectedly
high. One of such phenotypic biochemical tools; the CareStart G6PD RDT kit is developed to
overcome some of the challenges faced when one uses the existing routine G6PD screening
methods before patient management. The Kit is rapid, works in wide range of temperature
[16], uses small amounts of blood (Manufacturer’s manual) and not costly compared to other
commercially available G6PD test kits [17].
To the best of our knowledge, CareStart G6PD RDT kit has not been evaluated in a malarial
endemic area in an African setting as compared to what has been done largely by others else-
where. The use of the device for point-of-care testing has been described as feasible, not labour
intensive, require less training, not time involving, no special additional equipment and storage
conditions required and has the ability to detect G6PD deficient individuals [2, 16–20]. Majori-
ty of these evaluation studies which occurred outside Africa used venous blood samples except
Bancone et al, 2015 [20] which employed capillary blood collection from sterile finger prick to
assess the performance of the RDT kit.
We evaluated the diagnostic accuracy of the CareStart G6PD deficiency RDT kit using capil-
lary blood in a malarial endemic area in Ghana, Africa where G6PD deficiency is high and the
need for RDT to rapidly screen for G6PD deficiency is urgent. This is necessary to make a tool
available at point-of-care when Ghana adopts the recommendation of WHO to use fixed dose
of primaquine for malaria treatment and elimination programme.
Methods
Ethical statement
Ethical approval of the study procedures and consultations of records of potential participants
with known G6PD status to recruit was granted by the Kintampo Health Research Centre Insti-
tutional Ethics Committee (KHRC-IEC). The objectives and procedures of the study were
carefully explained to all potential participants to seek their written/thumb printed informed
consent to participate. Care-takers gave written informed consent on behalf of their minor
participants and also on behalf of their children who were between ages 12 and 17, who
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additionally gave their written/thumb printed informed assent to be part of the study. Partici-
pants were informed they were being contacted because of their previous involvement with the
Kintampo Health Research Centre for studies that involved G6PD testing which they gave
their written informed consent to be contacted anytime needful. Participants’ identity and rec-
ords were anonymized prior to analysis.
Study design
We adopted a cross-sectional study design to evaluate the performance of the CareStart G6PD
deficiency RDT kit among participants with known G6PD status (Normal and Deficient) from
previous studies carried out in the study area. This study was conducted between February
2013 and June 2013.
To calculate the sample size to carry out the performance evaluation, the team assumed an
expected Area under ROC curve of 0.80 compared to a Null hypothesis value of 0.68 [16] con-
sidering a 2:1 ratio of sample sizes in negative/positive groups at 95% CI with 80% power
(MedCalc version 12.5 software, Mariakerke, Belgium). A minimum of 174 participants com-
posed of G6PD Deficient (n = 58) and Normal (n = 116) was required to assess the diagnostic
performance of the kit. The team increased the sample size by assuming a 20% refusal rate and
the possibility of a prospective participant not available during recruitment in the field to gen-
erate the total listing that was sent to the field.
Study site
The study was carried out in the Kintampo North Municipal and Kintampo South District of
Ghana (Fig 1); two administrative areas where the population is periodically followed for
health indicator data [10]. The study site covers an area of 7162 Sq Km with a resident popula-
tion of approximately 140,000 [10]. The study area is located within the forest-savannah transi-
tional ecological zone in Ghana and subsistent farming is the predominant occupation. The
prevalence of malaria parasitemia is about 50% among children less than 10 years of age
(symptomatic/asymptomatic) with perennial malaria transmission and entomological inocula-
tion rate of 269 infective bites per person per year [7]. The prevalence of G6PD deficiency in
the community is about 7% to 19% [1, 11]. There are more than twelve (12) clinics and
three (3) hospitals within the study area. None of these health facilities performs the G6PD
Fig 1. Map of the study communities.
doi:10.1371/journal.pone.0125796.g001
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deficiency screening test as part of health service delivery except the research institution. Ma-
laria rapid diagnostic test are however available at all health facilities and also used by commu-
nity based health officers for malaria diagnosis.
Study population, participants selection and recruitment
Kintampo Health Research Centre carried out a population reference study and also a two-
year cohort study. G6PD deficiency testing was one of the laboratory investigations carried out
in the two studies. The database of the population of the two studies became the sampling
frame to select prospective participants to evaluate the diagnostic accuracy of the G6PD
RDT kit.
The number of G6PD Deficient and Normal participants with known G6PD study partici-
pants with known G6PD status from the previous studies were selected from the database
using MS Excel. The status of potential participants from the previous studies [21, 22] were de-
termined using PCR [23, 24] and quantitative spectrophotometric method [25, 26].
Selected individuals were initially visited at home, informed about the study and invited to
participate after consenting. Individuals who were present in the community and willingly
agreed to be part of the study were invited to a central point within the community to interact
with the study team. A prospective participant who refused consenting to be recruited was re-
placed from list of prospective participants with known G6PD status. Flow chart for study par-
ticipants’ selection and recruitment is presented in Fig 2.
The process of participants’ selection was as follows. The team consulted a database from
two previous studies that enrolled participants with their G6PD status established either with
PCR or quantitative method. The team randomly selected the needed number of positive/
deficient participants from the list of G6PD deficient individuals classified in the previous
study. Same random selection was done to get the number of negative/normal individuals from
the previous studies. Selected prospective participants from the previous studies were contacted
in the community, consented to participate in the current evaluation study. The approach
adopted in this study was not wholly community based survey and then presents the limitation
of estimating prevalence parameters like the NPV and PPV. We can only describe the sensitivi-
ty, specificity and the Area under the ROC curve. We did not assign randomization codes or
any special randomization technique. Simple randomization was adopted to fairly select any
participant with known G6PD status in the category of interest.
Participants’ sampling and data collection
G6PD deficiency test was done with CareStart G6PD deficiency RDT screening kit (Access
Bio. Inc., New Jersey, USA, LOT No. GP3A1) using capillary blood samples collected from
sterile finger prick. About 1.0–1.6ml of blood was collected after G6PD and malaria RDT test-
ing from the finger prick. The capillary blood sample collected into the EDTA microtainer test-
tubes were sent to the KHRC Clinical Laboratory to perform G6PD deficiency screening tests
using Trinity Biotech quantitative G6PD assay (Cat. No. 345UV, Trinity Biotech, St. Louis,
USA) and Trinity Biotech qualitative G6PD assay (Cat. No. 400K, Trinity Biotech, St. Louis,
USA). Trinity Biotech quantitative method for G6PD was adapted and performed on The Flex-
or E Clinical Chemistry analyser (Vital Scientific, The Netherlands). Quantitative and qualita-
tive analyses were performed on the fresh blood samples within a maximum of 48 hours after
the collection to determine levels of G6PD enzyme activity.
Accuracy of CareStartG6PD Deficiency RDT Kit
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Laboratory test procedures
Quantitative determination of G6PD activity. Using Trinity quantitative method: The
Trinity Biotech quantitative G6PD assay method was used as the gold standard [16]. The meth-
od is based on the spectrophotometric methods of Kornberg, 1955 [25] and Lohr et al, 1974
[26]. This involves the reduction of NADP to NADPH, by the G6PD enzyme in the presence of
glucose-6-phosphate to the formation of NADPH which is proportional to the G6PD enzyme
activity, measured spectrophotometrically at 340 nm (Table 1). The method is most accepted
and sensitive and has been widely used to evaluate most G6PD methods.
Fig 2. Flow chart of profile for study participants’ selection and recruitment.
doi:10.1371/journal.pone.0125796.g002
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Classification of G6PD deficiency. The classification of G6PD deficiency status, using
quantitation assay methods were based on population reference value G6PD activity of adjust-
ed male median estimated to be 5.5 U/g Hb ((Male Median = 5.5, Range (4.1–15.4)), Unpub-
lished data) established in the study area using the classification procedure described by
Domingo et al, 2013 [27]. The team classified and assessed the performance of the kit at en-
zyme activity levels<10% (n = 0),<20% (n = 1),<30% (n = 12),<40% (n = 14),<60%
(n = 23) and above the median of normal G6PD enzyme activity recorded of participants used
in this study. The population reference value G6PD activity was established using a population
of 1,353 sampled randomly from the study area. The population sampling and recruitment for
the data to establish this G6PD enzyme activity reference value are described in Dosoo et al,
2012 and Dosoo et al, 2014 [22, 28].
Using the Trinity Quantitative method, the G6PD deficiency status of participants were
classified as either “Normal” or “Deficient” at a cut-off of 4.1 U/g Hb. All participants who
measured G6PD enzyme activity<4.1 U/g Hb were classified as “Deficient” while those with
enzyme activity equal to or above 4.1 U/g Hb were considered “Normal”.
Qualitative determination of G6PD activity and deficiency classification. Using CareS-
tart G6PD deficiency screening test: The CareStart G6PD deficiency RDT format test, which is
a qualitative enzyme chromatographic test is based on the reduction of colourless nitro blue
tetrazolium dye to dark coloured formazan. The test kit requires minimal training and no spe-
cial expertise or additional equipment for use. Two microliters (2μl) of blood added into the
sample well with two drops of buffer into the buffer well gave the G6PD deficiency status of an
individual in 10 minutes. Samples with normal G6PD activity produce a distinct purple colour
background in the result window while no colour change was observed for samples with defi-
cient G6PD activity (Fig 3). Samples that produced a pale purple colour giving ambiguous Car-
eStart test results were for safety reasons called deficient, which would be the norm in a clinical
setting. This could result in a decrease in specificity. The performance of CareStart G6PD defi-
ciency RDT screening kit was stable in a temperature of 20°C to 32°C (was verified over a two-
day period with Libero Ti1 digital thermometer. Data not shown) (Table 1).
Using Trinity Qualitative method: The Trinity Biotech qualitative G6PD assay method uses
G6PD released from lysed erythrocytes to catalyze the conversion of glucose-6-phosphate to
6-phosphogluconate with reduction of NADP to NADPH. In the presence of phenazine meth-
osulfate (PMS), NADPH reduces a blue dye to the colourless form. The rate at which the colour
visually disappears in the reaction mixture is proportional to the G6PD content of red cells.
Disappearance of blue colour of the dye within 1 hour while incubating reaction mixture at
37°C denoted participant had NORMAL G6PD enzyme activity. DEFICIENT was when there
was no change in the blue colour (Table 1).
Table 1. An outline comparing some common factors of importance between the methods used for G6PD screening in the study.
TEST NAME TRINITY
QUANTITATIVE
TRINITY
QUALITATIVE
CARESTART G6PD RDT
(QUALITATIVE)
VOLUME OF SAMPLE NEEDED 10μl* 5μl* 2.0μl
APPROXIMATE TIME NEEDED TO READ RESULTS 20mins 1hr:5min 10mins
TEMPERATURE AT WHICH TEST IS STABLE
(Manufacturer package)
2°C–8°C 2°C–8°C 18°C–32°C
CAPABLE OF BEING USED FOR POINT-OF-CARE
SCREENING
No No Yes
*: Volume of blood to estimate Haemoglobin concentration is needed.
doi:10.1371/journal.pone.0125796.t001
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Full blood count analysis. Full Blood Count was determined using a validated ABXMi-
cros 60 analyzers (Horiba-ABX, Montpellier, France) to obtain the haemoglobin concentra-
tion, Red Blood Cells and White Blood Cell count levels of participants were used in the
calculation of the G6PD activity in the erythrocytes and malaria parasite density.
Fig 3. CareStartG6PD RDT screening kit with results interpretation. Results of kit labelled with
NORMAL and DEFICIENT interpretation.
doi:10.1371/journal.pone.0125796.g003
Accuracy of CareStartG6PD Deficiency RDT Kit
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Malaria diagnosis
Malaria RDT test kits (CareStartMalaria RDT (Access Bio. Inc., New Jersey, USA)) were used
to screen for malaria simultaneously with the G6PD RDT. Samples collected were transported
to the KHRC laboratory to prepare blood slides to examine for malaria parasites. Microscopic
examinations of thick and thin blood films were conducted to confirm malaria diagnosis. Thin
and thick peripheral blood smears prepared were read by two independent microscopists, and
by a third microscopist if the results were discordant on positivity or on parasite density, as de-
scribed by Adu-Gyasi et al, 2012 [29].
Data management and statistical analysis
Data was checked for completeness and consistency and all queries resolved after double data
entry using Microsoft Access software 2010. Cleaned data was analysed using Stata Software
version 12 (Stata Corporation, TX USA). The performance of G6PD deficiency RDT was ex-
pressed by calculating the sensitivity (SE), specificity (SP) and the Area under the Receiver Op-
erator Characteristics (ROC) curve for G6PD deficiency status using the Trinity quantitative
results as gold standard [16]. Differences in means and all reported parameters were considered
significant at 95% Confidence Intervals.
Quality Assurance
All 5 personnel involved in the various tests were trained before the start of the study. The
training included classifying a qualitative test outcome as ‘‘positive” or ‘‘negative” (deficient or
normal) as described by the manufacturer’s instructions. Qualitative tests were performed be-
fore the quantitative analysis. Personnel who performed the tests were blinded to the results of
each method and stage of testing. Quality control checks were performed for the Full Blood
Count on the automated haematology analyser with commercially available controls. The Car-
eStart G6PD deficiency RDT and Trinity Quantitative methods were controlled with two levels
of commercially prepared G6PD quality control (QC) (normal level, Cat. No. PD 2618 and de-
ficient level Cat. No. PD 2617 controls) samples from Randox.
Results
Study population
A total of 206 participants were recruited. About 57.8% (119/206) of the participants were
males and 42.2% (87/206) were females. The median age of the participants was 27 years
(range 2–85 years); 21.4% (44/206) of participants were less than or equal to ten years.
Comparing the performance of CareStartG6PD deficiency test method
to the routinely used methods
G6PD deficiency RDT and Trinity Biotech quantitative: The SE and SP of CareStart G6PD de-
ficiency RDT method were 100% and 72.1% using Trinity Biotech quantitative method as a
gold standard. The ROC was 0.86 (Table 2). Considering the performance of the kit at (0.6, 1.1,
1.7, 2.2, 3.3, 4.4, and>4.4) Ug/Hb of G6PD enzyme activity, a ROC of 0.94 was obtained as
presented in Fig 4. The sensitivity of the RDT kit was excellent at G6PD enzyme activity less
than 8.0 Ug/Hb.
G6PD deficiency RDT and Trinity Biotech qualitative: The SE and SP of CareStart G6PD
deficiency RDT method were 98.9% and 96.2% comparing to Trinity Biotech Qualitative meth-
od. The ROC was 0.98 (Table 2). When the Trinity biotech qualitative method was compared
Accuracy of CareStartG6PD Deficiency RDT Kit
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to the Trinity Biotech quantitative method as “gold standard” the SE and SP were 100% and
76.3% with a ROC of 0.88.
Comparing the performance of CareStartG6PD RDT kit by gender to
routinely used methods to screen for G6PD deficiency.
The diagnostic accuracy of CareStart G6PD RDT to screen for G6PD deficiency when com-
pared to Trinity biotech qualitative (P = 0.124) and Trinity biotech quantitative (P = 0.123)
method were not significantly affected by gender (Table 3).
Performance of CareStartG6PD deficiency RDT Kit among malaria
participants
Among the study participants, 26.2% (54/206) had positive malaria parasites using microscopy.
The performance of CareStart G6PD deficiency RDT was not affected significantly (P = 0.199)
when we considered participants that had malaria parasites infection compared to those that
had no malaria parasite (Fig 5). The difference in the Mean (±SE) of levels of G6PD enzyme ac-
tivity among participants with positive malaria parasites (95% CI, 13.0 (±1.81)) compared to
those with negative malaria parasites (95% CI, 14.4 (±1.0)) was not significant (P = 0.242).
Table 2. Performance of theCareStartG6PD deficiency RDT kit to other commercially available methods for screening G6PD deficiency.
Gold standard Deﬁcient Gold standard Normal
RDT
Diff. (n)
RDTnormal (n) RDT
Diff. (n)
RDTnormal (n) Sensitivity%
(95% CI)
Speciﬁcity%
(95% CI)
AUC(95% CI)
Type of Gold standard method
Trinity Biotech
Qualitative
90 1 4 102 98.9, (94.0, 100) 96.2 (90.6, 99.0) 0.98 (0.96,
1.00)
Trinity Biotech
Quantitative
67 0 32 106 100 (94.7, 100) 72.1 (64.1, 79.2) 0.86 (0.83,
0.90)
doi:10.1371/journal.pone.0125796.t002
Fig 4. ROC curve of RDT performance with plotted points of considered enzyme activity.
doi:10.1371/journal.pone.0125796.g004
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Fig 6, illustrates the distribution of the levels of G6PD enzyme activity among participants con-
sidering malaria parasite status.
Discussion
Early diagnosis of Glucose-6-phosphate dehydrogenase deficiency could avert the potentially
harmful effect of the deficiency encountered during patient management with primaquine [30,
31] which is being recommended to be administered at fixed dose with ACT for malaria elimi-
nation in endemic regions [15, 31]. The danger of treating patients with drugs that are contra-
indicated for individuals with this deficiency could range from mild to severe haemolysis.
Ghana does not use primaquine in the management of patients with malaria [12] since it is
mainly employed in treating patients with relapsing Plasmodium species infections. Adoption
of the WHO recommendation would mean deploying treatment with primaquine and ACTs in
most malaria endemic regions including Ghana especially with the target of eliminating
Table 3. Diagnostic performance ofCareStartG6PD RDT by gender compared to Trinity Biotech Quantitative and Qualitative methods for G6PD
deficiency screening.
Gold standard Deﬁcient Gold standard Normal
RDT
Diff. (n)
RDT
normal (n)
RDT
Diff. (n)
RDT
normal (n)
Sensitivity %
(95% CI)
Speciﬁcity %
(95% CI)
AUC
(95% CI)
Sex Type of Gold standard method
Males Trinity Biotech
Qualitative
57 0 1 58 100 (93.7, 100) 98.3 (90.9, 100) 0.99 (0.97,
1.00)
Trinity Biotech
Quantitative
50 0 10 59 100 (92.9, 100) 85.5 (75.0, 92.8) 0.93 (0.89,
0.97)
Females Trinity Biotech
Qualitative
33 1 3 44 97.1 (84.7, 99.9) 93.6 (82.5, 98.7) 0.95 (0.91,
1.00)
Trinity Biotech
Quantitative
17 0 22 47 100 (80.5, 100) 68.1 (55.8, 78.8) 0.84 (0.79,
0.90)
doi:10.1371/journal.pone.0125796.t003
Fig 5. Area under the Receiver Operator Characteristics (ROC) curve for G6PD RDT performance
considering malaria status of participants.
doi:10.1371/journal.pone.0125796.g005
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Plasmodium falciparum gametocytes[6, 15]. Implementation of the recommendation of
primaquine fixed dose by WHO faced a challenge of seldom availability of G6PD testing in
the field [31]. The CareStart G6PD RDT which has high and acceptable diagnostic perfor-
mance as assessed in this study could make G6PD testing available at point-of-care and allevi-
ate this challenge.
The SE and SP of the CareStartG6PD deficiency RDT compared to results from Trinity
quantitative method used as the “gold standard” in a high malaria endemic area in Africa was
higher than what was recorded in the evaluation study by Kim et al, 2011 [16]. This diagnostic
performance of the kit was acceptable and comparable to performance documented in other
studies that evaluated the G6PD RDT kit [17, 18, 20, 32]. It was evident from this study that the
test kit has the highest sensitivity at concentrations of G6PD enzyme activity less than 8 Ug/Hb.
This performance of the test kit successful in detecting individuals with lower G6PD enzyme ac-
tivity is comparable to what von Fricken et al, 2014 and Roca-Feltrer et al, 2014 [17, 18] estab-
lished which confirms its suitability [18, 19] as point-of-care device to screen for G6PD
deficiency before administration of any drug that can induce acute haemolysis. The perfor-
mance of the test kit was similar among participants with malaria parasites and those without
parasites using microscopy (Fig 5). This assuring information also presents the device as suitable
to facilitate the testing for G6PD deficiency before drugs are administered during malaria pa-
tients’ management in peripheral health facilities where laboratory services are absent [18, 20].
Similarly, the BinaxNow qualitative method has a good performance but the range of tem-
peratures (18°C to 25°C) [32] required to carry out this test could compromise on its use for
point-of-care testing in a resource deprived facility in the tropics where temperature may rise
up to 32°C [33]. It is also overly clear that in a resource constraint facility, other highly per-
forming rapid G6PD screening methods such as the Fluorescent Spot Test cannot be used
since additional equipment requirements and specified storage conditions are needed for the
testing processes making the methods expensive to be carried out [18–20].
Obviously, most of the methods available and accepted for routine screening of G6PD status
of patients are not suitable to be employed to screen for G6PD status of patients at point-of-
care in malaria endemic regions in the tropics where screening for G6PD is most needed.
Fig 6. Estimates of G6PD enzyme activity levels by malaria parasite status.
doi:10.1371/journal.pone.0125796.g006
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These rapid methods need sophisticated equipment and temperature regulation. Again, unlike
the available routine test methods that require a minimum of 5μl to 3000μl of blood depending
on the method to use, this screening kit requires a volume of 2ul of capillary blood to determine
the G6PD deficiency status of an individual in 10mins at a temperature range of 18°C to 32°C
(Table 1). This also makes the device acceptable for use among paediatric patients where large
volumes of samples needed for testing are matters of concern.
Limitations
None of the test cassettes had control window (Manufacturer’s manual). It would have been
preferable to have this in the design to control each test that is performed with the kit. Analyz-
ing each batch of samples with controls might not be cost effective. Also, the CareStart G6PD
deficiency RDT kit produce a purple colour to differentiate between normal and deficient sub-
jects (Manufacturer’s manual). Borderline results also produce a pale purple colour. This can
result in operator-to-operator variations due to the subjectivity of interpretation for qualitative
colormetric results. The development of a technique to semi-quantitate the results of the rapid
test would be helpful to minimise misinterpretation of RDT results as mentioned by others.
The study participants were selected from a pre-selected population with known G6PD sta-
tus. This presents the limitation of estimating prevalence parameters like the negative predic-
tive values (NPV) and positive predictive values (PPV). The team could only describe the
sensitivity, specificity and the Area under the ROC curve to assess the diagnostic performance
of the kit.
Conclusion
The results from this study suggest that the diagnostic performance of the CareStart G6PD
RDT is acceptable at determining the G6PD deficiency status in a high malaria endemic area in
Ghana, Africa. The CareStart G6PD RDT kit presents as an attractive tool for point-of-care
G6PD deficiency testing in areas with high temperatures and requires significantly less time
and training to implement. The G6PD RDT kit could be used to screen malaria patients before
administration of the fixed dose primaquine with ACT as recommended by the WHO.
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